{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:56:03Z","timestamp":1793908563825,"version":"4.8.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Glutamic acid decarboxylase (GAD) antibodies are associated with disabling conditions such as stiff person syndrome, temporal lobe epilepsy (TLE), limbic encephalitis, cerebellar ataxia (CA), and ocular movement disorders, which are usually chronic and difficult to treat. GAD-related TLE has poor response to anti-seizure medications and immune therapies, and epilepsy surgery is rarely successful. We report on a 47-year-old female with history of migraine, autoimmune thyroid disease, ankylosing spondylitis, and drug-resistant TLE. A video electroencephalography recorded frequent seizures with temporo-insular semiology, correlating to left temporal epileptiform activity and left mesiotemporal hyperintensity on magnetic resonance imaging. GAD autoimmunity was confirmed by very high GAD antibody titers in serum and cerebrospinal fluid. Steroids, immunoglobulins, and cyclophosphamide had no effect, and selective left amygdalectomy was performed based on very restricted hypermetabolism on positron-emission tomography. After transient seizure freedom, significant epilepsy improvement was observed in spite of memory decline. Transient worsening was noted 1 year later during diabetes mellitus manifestation and 5 years later during presentation of progressive CA, which stabilized on rituximab treatment. We believe this case illustrates the diversity and the frequent overlap of GAD-associated disorders, the need of early and aggressive immunotherapy in severe patients, as well as the possible benefit from epilepsy surgery in some GAD-TLE.<\/jats:p>","DOI":"10.3389\/fneur.2021.756668","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T04:37:30Z","timestamp":1642653450000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Case Report: Multisystem Autoimmune and Overlapping GAD65-Antibody-Associated Neurological Disorders With Beneficial Effect of Epilepsy Surgery and Rituximab Treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Petia","family":"Dimova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krassimir","family":"Minkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.3390\/ijms21103701","article-title":"Neurological syndromes asociated with anti-GAD antibodies","volume":"21","author":"Dade","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"577189","DOI":"10.1016\/j.jneuroim.2020.577189","article-title":"Immune-mediated epilepsy with GAD65 antibodies","volume":"341","author":"Li","year":"2020","journal-title":"J Neuroimmunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"17562864211003486","DOI":"10.1177\/17562864211003486","article-title":"GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions","volume":"14","author":"Tsiortou","year":"2021","journal-title":"TherAdvNeurolDisord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1093\/brain\/awn183","article-title":"Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association","volume":"131","author":"Saiz","year":"2008","journal-title":"Brain."},{"key":"B5","first-page":"609","article-title":"Outcome with respect to epileptic seizures,","volume-title":"Surgical Treatment of the Epilepsies","author":"Engel","year":"1993"},{"key":"B6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/jamaneurol.2016.5429","article-title":"Neurological autoantibody prevalence in epilepsy of unknown etiology","volume":"74","author":"Dubey","year":"2017","journal-title":"JAMA Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1468-1331.2011.03609.x","article-title":"Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies","volume":"19","author":"Falip","year":"2012","journal-title":"Eur J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ana.21917","article-title":"Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis","volume":"67","author":"Malter","year":"2010","journal-title":"Ann Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.seizure.2015.05.017","article-title":"Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies","volume":"30","author":"Malter","year":"2015","journal-title":"Seizure."},{"key":"B10","doi-asserted-by":"publisher","first-page":"577063","DOI":"10.1016\/j.jneuroim.2019.577063","article-title":"Predictive value of high titer of GAD65 antibodies in a case of limbic encephalitis","volume":"337","author":"Di Giacomo","year":"2019","journal-title":"J Neuroimmunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1017\/cjn.2016.13","article-title":"Limbic encephalitis associated with GAD65 antibodies: brief review of the relevant literature","volume":"43","author":"Gagnon","year":"2016","journal-title":"Can J Neurol Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1136\/jnnp-2015-310512","article-title":"Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study","volume":"87","author":"Moloney","year":"2016","journal-title":"J NeurolNeurosurg Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/14740338.2020.1763299","article-title":"Concerns about the safety of anti-TNF agents when treating rheumatic diseases","volume":"19","author":"Atzeni","year":"2020","journal-title":"Expert Opin Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.autrev.2013.09.002","article-title":"Demyelination and other neurological adverse events after anti-TNF therapy","volume":"13","author":"Kaltsonoudis","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1159\/000499754","article-title":"Rapid changes of thyroid function in a young woman with autoimmune thyroid disease","volume":"28","author":"Trummer","year":"2019","journal-title":"Med PrincPract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fneur.2018.01143","article-title":"Hippocampus and insula are targets in epileptic patients with glutamic acid decarboxylase antibodies","volume":"9","author":"Falip","year":"2019","journal-title":"Front Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/jnnp.2003.023333","article-title":"Localising and lateralising value of ictal piloerection","volume":"75","author":"Loddenkemper","year":"2004","journal-title":"J NeurolNeurosurg Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.0013-9580.2004.68903.x","article-title":"Clinical manifestations of insular lobe seizures: a stereo-electroencephalographic study","volume":"45","author":"Isnard","year":"2004","journal-title":"Epilepsia."},{"key":"B19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.seizure.2014.04.013","article-title":"Pilomotor seizures: an autonomic semiology of limbic encephalitis?","volume":"23","author":"Rocamora","year":"2014","journal-title":"Seizure."},{"key":"B20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1684\/j.1950-6945.2005.tb00123.x","article-title":"Pilomotor seizures and status in non-paraneoplastic limbic encephalitis","volume":"7","author":"Wieser","year":"2005","journal-title":"Epileptic Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00415-015-8002-2","article-title":"Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings","volume":"263","author":"Baysal-Kirac","year":"2016","journal-title":"J Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fneur.2020.00061","article-title":"Pilomotor seizures in a patient with LGI1 encephalitis","volume":"11","author":"Yang","year":"2020","journal-title":"Front Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1684\/epd.2017.0946","article-title":"Refractory chronic epilepsy associated with neuronal auto-antibodies: could perisylvian semiology be a clue?","volume":"19","author":"Gillinder","year":"2017","journal-title":"Epileptic Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1007\/s00415-013-7048-2","article-title":"Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types","volume":"260","author":"Baumgartner","year":"2013","journal-title":"J Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/diagnostics10060356","article-title":"18F-FDG-PET imaging patterns in autoimmune encephalitis: impact of image analysis on the results","volume":"10","author":"Moreno-Ajona","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.yebeh.2016.10.016","article-title":"Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis","volume":"65","author":"Hansen","year":"2016","journal-title":"Epilepsy Behav."},{"key":"B28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.eplepsyres.2016.12.010","article-title":"Epilepsy surgery in drug-resistant temporal lobe epilepsy associated with neuronal antibodies","volume":"129","author":"Carre\u00f1o","year":"2017","journal-title":"Epilepsy Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fneur.2018.00579","article-title":"Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: the interplay between immunotherapy and anti-epileptic drugs","volume":"9","author":"M\u00e4kel\u00e4","year":"2018","journal-title":"Front Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/archneur.58.2.225","article-title":"Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients","volume":"58","author":"Honnorat","year":"2001","journal-title":"Arch Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40673-015-0034-y","article-title":"Guidelines for treatment of immune-mediated cerebellar ataxias","volume":"2","author":"Mitoma","year":"2015","journal-title":"Cerebellum Ataxias."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/jamaneurol.2014.1011","article-title":"Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy","volume":"71","author":"Ari\u00f1o","year":"2014","journal-title":"JAMA Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.756668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T16:58:57Z","timestamp":1726505937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.756668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":32,"alternative-id":["10.3389\/fneur.2021.756668"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.756668","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"article-number":"756668"}}